Evidence map›Paper›PMID 29199958›Full record

ArticleeLife2017

Limian Cao, Pengfei Zhang, Jinming Li, Mian Wu

Open access · goldAbstract read
In one paragraph

Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. mActa pharmaceutica Sinica. B · 2025
    Review
  6. Article
  7. Article
  8. Computational and structural biotechnology journal · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Decoding mGenes & diseases · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Post-transcriptional regulation of erythropoiesis.Blood science (Baltimore, Md.) · 2023
    Review
  18. Vascular mimicry induced by mCell death discovery · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Limian Cao *CAS Key Laboratory of Innate Immunity and Chronic Disease, CAS Center for Excellence in Molecular Cell Science, Innovation Center for Cell Signaling Network, School of Life Sciences, University of Science & Technology of China, Hefei, China.
Pengfei Zhang *CAS Key Laboratory of Innate Immunity and Chronic Disease, CAS Center for Excellence in Molecular Cell Science, Innovation Center for Cell Signaling Network, School of Life Sciences, University of Science & Technology of China, Hefei, China.
Jinming LiTranslational Research Institute, Henan Provincial People's Hospital, School of Medicine, Henan University, Zhengzhou, China.
Mian WuCAS Key Laboratory of Innate Immunity and Chronic Disease, CAS Center for Excellence in Molecular Cell Science, Innovation Center for Cell Signaling Network, School of Life Sciences, University of Science & Technology of China, Hefei, China.ORCID http://orcid.org/0000-0002-2714-0500
University of Science and Technology of China · CNHenan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclin D1 is a critical regulator of cell cycle progression and works at the G1 to S-phase transition. Here, we report the isolation and characterization of the novel c-Myc-regulated lncRNA

Indexed as

Gene Expression RegulationRNA StabilityCyclin D1HumansRNA-Binding ProteinsRNA, Long NoncodingCCND1 protein, humanCNBP protein, humanCyclin D1RNA-Binding ProteinsRNA, Long Noncodingcancer biologyCCND1cell biologyCNBPE. colihumanLASTmRNA stability

Identifiers

PMID29199958
PMCPMC5739540
OpenAlexW2774959727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.